Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Post by Pimpovishon Jan 24, 2021 7:27pm
359 Views
Post# 32372082

Balaenoptera musculus

Balaenoptera musculus

 

It’s going to be an interesting week. One of the largest whales I know seems to finally be motivated to buy V.HEM. This guy is big but for privacy reasons I cannot reveal his identity. No doubt Friday’s press release has triggered a call to action. My group was approached for a million share cross. However, no one is biting. As a matter of fact, more than a few of us will be adding rather than even thinking of subtracting. This whale was told at 1.5 cents (equivalent to 30 cents post rollback). This whale was also in Sernova so he is fully cognizant of the parabolic share price dynamics in the biotech sector. Anyone looking for size is going to have to pay up. My senses are telling me we may be entering dollarland very soon.

<< Previous
Bullboard Posts
Next >>